FindTrial
Sign In

Farletuzumab

DRUG5 trials

Sponsors

Morphotek, Eisai Inc.

Conditions

Adenocarcinoma of the LungFallopian Tube CancerOvarian CancerPeritoneal NeoplasmsPlatinum-Sensitive Ovarian Cancer in First RelapseResectable, Non-functioning Pituitary Adenoma

Phase 2

Effectiveness of MORAb-003 in Women With Ovarian Cancer Who Have Relapsed After Platinum-Based Chemotherapy
CompletedNCT00318370
MorphotekFallopian Tube Cancer, Ovarian Cancer, Peritoneal Neoplasms
Start: 2006-05-31End: 2010-06-30Updated: 2015-09-09
Exploratory Study of Farletuzumab to Treat Resectable, Non-functioning Pituitary Adenomas
WithdrawnNCT01203618
MorphotekResectable, Non-functioning Pituitary Adenoma
Start: 2011-02-28End: 2013-08-31Updated: 2013-11-04
A Safety and Efficacy Study of Farletuzumab in Participants With Adenocarcinoma of the Lung
CompletedNCT01218516
MorphotekAdenocarcinoma of the Lung
Start: 2011-06-27End: 2013-11-01Updated: 2020-08-20
A Study to Assess the Efficacy and Safety of Farletuzumab (MORAb 003) in Combination With Carboplatin Plus Paclitaxel or Carboplatin Plus Pegylated Liposomal Doxorubicin (PLD) in Participants With Low CA125 Platinum-sensitive Ovarian Cancer
CompletedNCT02289950
Eisai Inc.Platinum-Sensitive Ovarian Cancer in First Relapse
Start: 2015-03-19End: 2020-08-13Updated: 2021-09-02

Phase 3

Efficacy and Safety of Farletuzumab (MORAb-003) in Combination With Carboplatin and Taxane in Participants With Platinum-sensitive Ovarian Cancer in First Relapse
TerminatedNCT00849667
MorphotekOvarian Cancer
Start: 2009-04-16End: 2013-04-12Updated: 2022-12-30

Related Papers

Randomized phase II trial of farletuzumab plus chemotherapy versus placebo plus chemotherapy in low CA-125 platinum-sensitive ovarian cancer.
2023-02-0715 citations
A randomized, double-blind, placebo-controlled, phase II study to assess the efficacy and safety of farletuzumab (MORAb-003) in combination with carboplatin plus either paclitaxel or pegylated liposomal doxorubicin (PLD) in subjects with low CA125 platinum-sensitive ovarian cancer.
Journal of Clinical Oncology2016-05-202 citations